米拉贝隆治疗女性腺性膀胱炎合并膀胱过度活动症的临床价值  

Clinical Value of Mirabelone in the Treatment of Female Cystitis Glandu⁃laris Combined with Overactive Bladder

作　　者：蒿振明 高美珠[1] 柴克强[1] 刘昱林 胡进博 HAO Zhenming;GAO Meizhu;CHAI Keqiang;LIU Yulin;HU Jinbo(Department of Urology,Baiyin First People's Hospital,Baiyin 730900,Gansu,China)

机构地区：[1]白银市第一人民医院泌尿科,甘肃白银730900

出　　处：《系统医学》2024年第19期27-30,共4页Systems Medicine

基　　金：白银市第一人民医院培育项目(2021PY-09)。

摘　　要：目的 探讨米拉贝隆治疗女性腺性膀胱炎(cystitis glandularis,CG)合并膀胱过度活动症(overactive bladder,OAB)的临床价值。方法 非随机选取2021年1月—2023年12月白银市第一人民医院收治的82例女性CG合并OAB患者,按治疗方式不同分为对照组和观察组,各41例。对照组采用索利那新片治疗,观察组在对照组基础上增用米拉贝隆。比较两组排尿情况、尿动力学指标的检测结果、临床疗效及不良反应。结果 持续用药12周后,观察组排尿次数、夜尿次数、尿急次数、尿失禁次数均少于对照组,差异有统计学意义(P均<0.05)。持续用药12周后,观察组平均尿流率、尿量均大于对照组,残余尿量小于对照组,差异有统计学意义(P均<0.05)。观察组的总有效率为95.12%(39/41),高于对照组的78.05%(32/41),差异有统计学意义(χ^(2)=5.145,P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 米拉贝隆治疗女性CG合并OAB的疗效良好,可改善患者的排尿情况,且联合用药不增加不良反应风险。Objective To investigate the clinical value of mirabegron in the treatment of female cystitis glandularis(CG)with overactive bladder(OAB).Methods From January 2021 to December 2023,eighty-two female CG patients with OAB admitted to the First People's Hospital of Baiyin City were non-randomly selected and divided into control group and observation group according to different treatment methods,with forty-one cases in each group.The control group was treated with solifenacin tablets,and the observation group was treated with mirabegron on the basis of the control group.The urination,urodynamic indexes,clinical efficacy and adverse reactions were compared between the two groups.Results After 12 weeks of continuous medication,the number of urination,nocturia,urgency and urinary incontinence in the observation group were less than those in the control group,and the differences were statistically significant(all P<0.05).After 12 weeks of continuous medication,the average urinary flow rate and urine volume of the observation group were higher than those of the control group,and the residual urine volume was lower than that of the control group,the differences were statistically significant(all P<0.05).The total effective rate of the observation group was 95.12%(39/41),which was higher than 78.05%(32/41)of the control group,and the difference was statisti-cally significant(χ^(2)=5.145,P<0.05).There was no significant difference in the total incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion Mirabegron is effective in the treatment of female CG combined with OAB,which can improve the urination of patients,and the combination does not increase the risk of adverse reactions.

关 键 词：腺性膀胱炎 膀胱过度活动症 米拉贝隆 临床疗效 

分 类 号：R694[医药卫生—泌尿科学]